4th June 2024
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Company")
AGM Statement
Venture Life (AIM: VLG), a leader in
developing, manufacturing and commercialising products for the
self-care market, will hold its Annual General Meeting
("AGM") at 10:00am this
morning. At the meeting, the Group's Chair, Paul McGreevy will make
the following statement:
"On behalf of the Board, I would
once again like to take this opportunity to thank Venture Life's
employees for their ongoing commitment and support. The business
continues to perform well and our increased focus on promoting the
VLG owned brands is delivering pleasing results, with an additional
35 new listings secured within UK retail since the beginning of the
year. We remain confident about the outlook for the year ahead and
our ability to deliver full year performance in line with
management's expectations. Further commentary over first half
trading will be provided as part of our usual business update in
July."
Resolution 10 has been withdrawn
prior to the commencement of the AGM as certain of the Company's
shareholders had indicated that they would not be supportive of the
resolution. Resolution 10 was the proposed disapplication of
pre-emption rights in order for the Board to allot equity
securities of up to an aggregate nominal amount of £37,949.46. The
Board had proposed Resolution 10 as it considered the flexibility
afforded by this authority to be in the best interests of the
Company and will consider further engagement with the opposing
shareholders on this matter in the future.
For
further information, please contact:
Venture Life Group
PLC
+44 (0) 1344 578004
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
Cavendish Capital Markets Limited (Nomad and
Broker)
+44 (0) 20 7720 0500
Stephen Keys / Camilla Hume
(Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international
consumer self-care company focused on developing, manufacturing and
commercialising products for the global self-care market. With
operations in the UK, Italy, and Sweden, the Group's product
portfolio includes some key products such as the Balance Active
range in the area of women's intimate healthcare, the Earol®
product line in ENT care, the Lift and Glucogel product ranges for
energy and glucose management and hypoglycaemia, the UltraDEX and
Dentyl oral care product ranges, products for fungal infections and
proctology, and dermo-cosmetics for addressing the signs of ageing.
Its products are sold in over 90 countries worldwide.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied direct by the company
to retailers, elsewhere they are supplied by the Group's
international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the Group also
provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.